Application

BASILEA LABORATORIES

Basilea Pharmaceutica AG

Trademark/Service Mark Application, Principal Register

PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97578739
Filing Date: 09/05/2022

The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 97578739
MARK INFORMATION
*MARK BASILEA LABORATORIES
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT BASILEA LABORATORIES
MARK STATEMENT The mark consists of standard characters, without claim to any particular font style, size, or color.
REGISTER Principal
APPLICANT INFORMATION
*OWNER OF MARK Basilea Pharmaceutica AG
*MAILING ADDRESS Grenzacherstrasse 487
*CITY Basel
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY Switzerland
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
4058
*EMAIL ADDRESS XXXX
LEGAL ENTITY INFORMATION
TYPE corporation
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION Switzerland
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS 001 
*IDENTIFICATION Diagnostic preparations for clinical or medical laboratory use; Diagnostic reagents for clinical or medical laboratory use
FILING BASIS SECTION 1(b)
INTERNATIONAL CLASS 005 
*IDENTIFICATION Pharmaceutical and veterinary preparations for the treatment or prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary preparations for the treatment of infections caused by bacteria, fungi, viruses and rheumatoid arthritis; Pharmaceutical and veterinary preparations for the treatment of diseases, disorders and conditions in the area of oncology
FILING BASIS SECTION 1(b)
ADDITIONAL STATEMENTS SECTION
DISCLAIMER No claim is made to the exclusive right to use LABORATORIES apart from the mark as shown.
ATTORNEY INFORMATION
NAME Evan A. Raynes
ATTORNEY BAR MEMBERSHIP NUMBER XXX
YEAR OF ADMISSION XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY XX
FIRM NAME Symbus Law Group PLLC
STREET 1775 I Street, NW, Suite 1150
CITY Washington
STATE District of Columbia
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
ZIP/POSTAL CODE 20006
PHONE 202-258-0652
EMAIL ADDRESS eraynes@symbus.com
OTHER APPOINTED ATTORNEY Symbus Law Group PLLC
CORRESPONDENCE INFORMATION
NAME Evan A. Raynes
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE eraynes@symbus.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) trademarks@symbus.com
FEE INFORMATION
APPLICATION FILING OPTION TEAS Standard
NUMBER OF CLASSES 2
APPLICATION FOR REGISTRATION PER CLASS 350
*TOTAL FEES DUE 700
*TOTAL FEES PAID 700
SIGNATURE INFORMATION
SIGNATURE /Evan A. Raynes/
SIGNATORY'S NAME Evan A. Raynes
SIGNATORY'S POSITION Attorney of record, DC bar member
SIGNATORY'S PHONE NUMBER 202-258-0652
DATE SIGNED 09/05/2022
SIGNATURE METHOD Signed directly within the form



PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number


Trademark/Service Mark Application, Principal Register

Serial Number: 97578739
Filing Date: 09/05/2022

To the Commissioner for Trademarks:

MARK: BASILEA LABORATORIES (Standard Characters, see mark)
The literal element of the mark consists of BASILEA LABORATORIES. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Basilea Pharmaceutica AG, a corporation of Switzerland, having an address of
      Grenzacherstrasse 487
      Basel 4058
      Switzerland
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 001:  Diagnostic preparations for clinical or medical laboratory use; Diagnostic reagents for clinical or medical laboratory use
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 005:  Pharmaceutical and veterinary preparations for the treatment or prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary preparations for the treatment of infections caused by bacteria, fungi, viruses and rheumatoid arthritis; Pharmaceutical and veterinary preparations for the treatment of diseases, disorders and conditions in the area of oncology
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.


Disclaimer
No claim is made to the exclusive right to use LABORATORIES apart from the mark as shown.


The owner's/holder's proposed attorney information: Evan A. Raynes. Other appointed attorneys are Symbus Law Group PLLC. Evan A. Raynes of Symbus Law Group PLLC, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      1775 I Street, NW, Suite 1150
      Washington, District of Columbia 20006
      United States
      202-258-0652(phone)
      eraynes@symbus.com

Evan A. Raynes submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:
      Evan A. Raynes
       PRIMARY EMAIL FOR CORRESPONDENCE: eraynes@symbus.com
       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): trademarks@symbus.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $700 has been submitted with the application, representing payment for 2 class(es).

Declaration

Declaration Signature

Signature: /Evan A. Raynes/   Date: 09/05/2022
Signatory's Name: Evan A. Raynes
Signatory's Position: Attorney of record, DC bar member
Signatory's Phone Number: 202-258-0652
Signature method: Signed directly within the form
Payment Sale Number: 97578739
Payment Accounting Date: 09/06/2022

Serial Number: 97578739
Internet Transmission Date: Mon Sep 05 18:39:31 ET 2022
TEAS Stamp: USPTO/BAS-XXX.XX.XXX.XX-2022090518393255
1215-97578739-8208951acbe164af7166e02143
d01b7f28c7b69518a5e268b83b495c9b3465fa0-
CC-39310045-20220905183659880293

Application [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed